Evaluation of Health Outcomes in Iraqi Patients With Prostate Cancer Who Underwent Radiotherapy
Keywords:
Prostate cancer (PC), Symptoms, Radiotherapy Treatment, Complications, General Health Quality of Life (EORTC QLQ-C30) QuestionnaireAbstract
Prostate cancer is common globally, with great strain on patient-reported health-related quality of life (HRQoL). This study aimed to assess general health quality of life in prostate cancer patients after radiotherapy treatment. A study was conducted on 80 prostate cancer patients who underwent radiotherapy at different hospitals in Karbala, Iraq, during a one-year follow-up period between February 2023 and February 2024. Demographic and surgical data were recorded for prostate cancer patients during the follow-up period. This study assessed patients' quality of life after completing radiotherapy, with all patients completing this quality of life questionnaire—a total of patients with prostate cancer (80) data enrolled in our study. The most symptoms were correlated with PC severity, include Urinary difficulties (85%) and fatigue (77.5%). Post RT procedure, short-term complications were 32.5%, where urinary incontinence with 11.25% and erectile dysfunction with 16.25%, while long-term complications were 40%, where included persistent erectile dysfunction got 25%. In the assessment of the quality of life, we found improving in physical functioning with 81.1 ± 6.6, diarrhea with 74.6 ± 12.5, and pain with 83.3 ± 6.2, while impaired in sexual functioning with 56.5 ± 4.8. This study demonstrates that patients with prostate cancer undergoing radiotherapy experience enhanced general well-being and improved quality of life. However, concurrent findings indicate a decline in sexual function.
References
Islami F, Ward EM, Sung H, et al. Annual report to the nation on the status of cancer, part 1: national cancer statistics. J Natl Cancer Inst 2021;113:1648-69.
US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA 2018;319:1901-13.
Desai MM, Cacciamani GE, Gill K, et al. Trends in incidence of metastatic prostate cancer in the US. JAMA Netw Open 2022; 5 (3):e222246.
Jemal A, Culp MB, Ma J, Islami F, Fedewa SA. Prostate cancer incidence 5 years after US Preventive Services Task Force recommendations against screening. J Natl Cancer Inst 2021;113:64-71.
Lane JA, Donovan JL, Davis M, et al. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol 2014;15:1109- 18.
Donovan JL, Young GJ, Walsh EI, et al. A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. J Clin Epidemiol 2018;96:35-46.
D’Amico AV. Treatment or monitoring for early prostate cancer. N Engl J Med 2016;375:1482-3.
Sternberg CN, Beltran H. Prostate cancer in 2016: improved outcomes and precision medicine come within reach. Nat Rev Urol 2017;14:71-2.
Wang LL, Wallis CJD, Sathianathen N, et al. ‘ProtecTion’ from overtreatment: does a randomized trial finally answer the key question in localized prostate cancer? BJU Int 2017;119:513-4.
Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005;173:1938-42.
D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
Gnanapragasam VJ, Bratt O, Muir K, et al. The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study. BMC Med 2018;16:31.
Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes 12 years after localized prostate cancer treatment. NEJM Evid 2023;2 (4). DOI: 10.1056/ EVIDoa2300018.
Hamdy FC, Donovan JL, Lane JA, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375:1415-24.
Hamdy FC, Donovan JL, Lane JA, et al. Active monitoring, radical prostatectomy, and radical radiotherapy in PSA-detected clinically localised prostate cancer: the Protect three-arm RCT. Health Technol Assess 2020;24:1-176.
Mayles WPM, Moore AR, Aird EGA, et al. Questionnaire-based quality assurance for the RT01 trial of dose escalation in conformal radiotherapy for prostate cancer (ISRCTN 47772397). Radiother Oncol 2004;73:199-207.
Mason MD, Moore R, Jones G, et al. Radiotherapy for prostate cancer: is it ‘what you do’ or ‘the way that you do it’? A UK perspective on technique and quality assurance. Clin Oncol (R Coll Radiol) 2016;28 (9):e92-e100.
Williams NJ, Hill EM, Ng SY, et al. Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial — lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer). BMC Med Res Methodol 2015;15:6.
Metcalfe C, Peters TJ, Hamdy FC. Prostate Testing for Cancer and Treatment (ProtecT) study. Statistical analysis plan — 15 years: version 1.0 19th November 2020.
Bauer P. Multiple testing in clinical trials. Stat Med 1991;10:871-89. 21. Prostate cancer: diagnosis and management. National Institute for Health and Care Excellence, 2021.
Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically localized prostate cancer: AUA/ASTRO guideline, part i: introduction, risk assessment, staging, and risk-based management. J Urol 2022;208:10-8.
Bryant RJ, Oxley J, Young GJ, et al. The ProtecT trial: analysis of the patient cohort, baseline risk stratification, and disease progression. BJU Int 2020;125:506- 14.
Cooper CS, Eeles R, Wedge DC, et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet 2015;47:367-72.
Erickson A, He M, Berglund E, et al. Spatially resolved clonal copy number alterations in benign and malignant tissue. Nature 2022;608:360-7.
D’Amico AV. Active surveillance versus treatment of prostate cancer: should metastasis be the primary endpoint? J Clin Oncol 2017;35:1638-40.
Gharzai LA, Jiang R, Wallington D, et al. Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. Lancet Oncol 2021;22:402-10.
Wilt TJ, Vo TN, Langsetmo L, et al. Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol 2020;77:713-24.
Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy, or watchful waiting in prostate cancer — 29-year follow-up. N Engl J Med 2018;379:2319- 29.
